fbpx
Loading
  • Twitter
  • LinkedIn
  • Facebook
  • Mail
  • Rss
  • Login
    • Password Reset
  • Register
Contacts us @ MediPr.org
Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong Kong
  • Health
  • About MediPaper
  • Search
  • Menu
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share by Mail

Conference Support

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology


Medical Writer: Stijn van den Borne, MSc
Updated: 11 September 2017

Our Experience

YOU MAY ALSO LIKE

ERAS guidelines for antenatal and preoperative care in caesarean delivery 1

ERAS guidelines for antenatal and preoperative care in caesarean delivery

https://medi-paper.com/wp-content/uploads/2019/01/ERAS-guidelines-for-antenatal-and-preoperative-care-in-caesarean-delivery-1.jpg 814 1500 Anaesthesiology.asia http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png Anaesthesiology.asia2019-01-21 13:54:592019-01-21 22:02:18ERAS guidelines for antenatal and preoperative care in caesarean delivery
Dr Paul Kessler - Euroanaesthesia 2018 - Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements©Aspen Pharmacare

Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements

https://medi-paper.com/wp-content/uploads/2018/12/Dr-Paul-Kessler-Euroanaesthesia-2018-Awake-Sedated-or-Anaesthetised-for-Regional-Anaesthesia-Block-Placements.png 539 800 Anaesthesiology.asia http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png Anaesthesiology.asia2018-12-26 16:49:292019-01-23 13:34:18Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements
Dr Ngai LIU - Euroanaesthesia 2018 - Closed-Loop or Automated Titration of IV Anaesthesia Impact on Routine Anaesthesia©Aspen Pharmacare

Closed-Loop or Automated Titration of IV Anaesthesia: Impact on Routine Anaesthesia

https://medi-paper.com/wp-content/uploads/2018/12/Dr-Ngai-LIU-Euroanaesthesia-2018-Closed-Loop-or-Automated-Titration-of-IV-Anaesthesia-Impact-on-Routine-Anaesthesia-e1548221779756.png 444 800 Anaesthesiology.asia http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png Anaesthesiology.asia2018-12-25 00:45:102019-01-23 13:33:53Closed-Loop or Automated Titration of IV Anaesthesia: Impact on Routine Anaesthesia
Meta-analysis TIVA with propofol lowers post-operative nausea, vomiting, and pain

Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

https://medi-paper.com/wp-content/uploads/2018/11/Meta-analysis-TIVA-with-propofol-lowers-post-operative-nausea-vomiting-and-pain.jpg 861 1500 Anaesthesiology.asia http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png Anaesthesiology.asia2018-11-27 15:43:582018-11-28 10:18:56Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain
PreviousNext

Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology.

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology (CSA), held from 7-10 September 2017 in Zhengzhou, Henan Province, PR China.

We would like to extend our gratitude to the inviting partner, the CSA, and doctors for making time to meet our medical writer.

The Annual Meeting of the CSA, the official anaesthetist chapter of the Chinese Medical Association, is the largest anaesthesiology meeting in China.

  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
PreviousNext
123456789

© Copyright 2017 – MediPaper – 25th Annual Meeting of the Chinese Society of Anaesthesiology – CSA2017 – 中华医学会第25 次全国麻醉学术年会

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share by Mail

You may also like

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

https://medi-paper.com/wp-content/uploads/2019/06/ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-.png 1000 750 Stijn van den Borne, MSc http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png Stijn van den Borne, MSc2019-06-12 14:12:322019-06-12 16:51:35ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised
paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

https://medi-paper.com/wp-content/uploads/2019/05/ASCO-2019-breast-cancer-TNBC-MBC-ABC-ASCO19-MONALEESA-7-TRINITI-1-FAKTION-TBCRC030-NeoSTOP-ETNA-GeparOLA-KRISTINE-PREDIX-CLEOPATRA-HERITAGE-SOPHIA-NALA-IMpassion-130-Tapur-Colet.jpg 1000 1500 Stijn van den Borne, MSc http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png Stijn van den Borne, MSc2019-06-03 16:53:572019-06-04 14:34:55ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

Venetoclax FDA approved for CLL and SLL

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png News Feed2019-05-15 16:19:292019-05-23 12:36:08Venetoclax FDA approved for CLL and SLL

FDA approves avelumab plus axitinib for renal cell carcinoma

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png Stijn van den Borne, MSc2019-05-14 16:22:572019-05-22 22:49:14FDA approves avelumab plus axitinib for renal cell carcinoma

Ramucirumab FDA approved for hepatocellular carcinoma

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png News Feed2019-05-10 16:24:042019-05-23 11:58:38Ramucirumab FDA approved for hepatocellular carcinoma

T-DM1 FDA approved for early breast cancer

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png News Feed2019-05-03 16:24:342019-05-22 22:14:15T-DM1 FDA approved for early breast cancer

Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png News Feed2019-05-02 16:25:032019-05-22 22:14:36Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation
Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

https://medi-paper.com/wp-content/uploads/2019/04/Can-a-novel-temporary-and-fully-resorbable-surgical-implant-improve-the-outcome-of-common-hockey-and-soccer-injuries.jpg 1000 1500 Stijn van den Borne, MSc http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png Stijn van den Borne, MSc2019-04-26 20:05:262019-04-26 20:12:32Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed http://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1552057222840.png News Feed2019-04-26 00:34:542019-04-26 00:38:58Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients
PreviousNext
1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2017 – MediPaper – CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology

Therapeutic Areas

Get access to restricted content via WeChat

MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港 Wechat

Newsletter

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

 MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | Medical Writer Jobs | MediNews.asia | Anaesthesiology.asia
© 2016-2019 MediPaper Medical Communications Ltd. | Website by [’mediPr] | Medical Writer Hong Kong | 醫學寫作 | 醫學作家香港 | Privacy Policy | Terms of Service | Cookie Policy
  • Twitter
  • LinkedIn
  • Facebook
  • Mail
  • Rss
Latest global trends of health measure and impact on survival rate Latest global trends of health measure and impact on survival rate Nivolumab Renal Cell Cancer Symposium Highlight Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds: